Enterprise Financial Services Corp Takes $200,000 Position in Boston Scientific Co. (NYSE:BSX)

Enterprise Financial Services Corp purchased a new stake in shares of Boston Scientific Co. (NYSE:BSX) during the fourth quarter, Holdings Channel reports. The fund purchased 2,242 shares of the medical equipment provider’s stock, valued at approximately $200,000.

Other hedge funds have also recently made changes to their positions in the company. Van ECK Associates Corp increased its holdings in shares of Boston Scientific by 18.1% during the third quarter. Van ECK Associates Corp now owns 57,894 shares of the medical equipment provider’s stock valued at $5,063,000 after acquiring an additional 8,882 shares in the last quarter. Impax Asset Management Group plc lifted its position in shares of Boston Scientific by 17.5% during the 3rd quarter. Impax Asset Management Group plc now owns 5,470,174 shares of the medical equipment provider’s stock valued at $457,138,000 after buying an additional 815,403 shares during the last quarter. Concurrent Investment Advisors LLC lifted its position in shares of Boston Scientific by 5.8% during the 3rd quarter. Concurrent Investment Advisors LLC now owns 9,724 shares of the medical equipment provider’s stock valued at $815,000 after buying an additional 530 shares during the last quarter. M&G PLC purchased a new position in shares of Boston Scientific during the 3rd quarter valued at $1,327,000. Finally, Capital Performance Advisors LLP purchased a new position in shares of Boston Scientific during the 3rd quarter valued at $30,000. 89.07% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on BSX. JPMorgan Chase & Co. upped their price target on Boston Scientific from $100.00 to $110.00 and gave the company an “overweight” rating in a research report on Monday, December 16th. Deutsche Bank Aktiengesellschaft upgraded Boston Scientific from a “hold” rating to a “buy” rating and set a $108.00 price objective on the stock in a research note on Friday, January 10th. Argus set a $130.00 price objective on Boston Scientific in a research note on Tuesday, February 18th. Morgan Stanley boosted their price objective on Boston Scientific from $100.00 to $120.00 and gave the company an “overweight” rating in a research note on Thursday, February 6th. Finally, Royal Bank of Canada upped their target price on Boston Scientific from $105.00 to $116.00 and gave the stock an “outperform” rating in a research note on Thursday, February 6th. Two analysts have rated the stock with a hold rating, twenty-one have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $108.91.

Boston Scientific Stock Down 1.6 %

Shares of NYSE:BSX opened at $99.15 on Friday. Boston Scientific Co. has a 52-week low of $65.52 and a 52-week high of $107.17. The firm has a market capitalization of $146.33 billion, a P/E ratio of 79.32, a P/E/G ratio of 2.79 and a beta of 0.77. The stock has a 50 day moving average price of $100.45 and a 200-day moving average price of $91.19. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.02 and a current ratio of 1.08.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $0.70 earnings per share for the quarter, beating analysts’ consensus estimates of $0.65 by $0.05. Boston Scientific had a return on equity of 17.80% and a net margin of 11.07%. As a group, equities research analysts anticipate that Boston Scientific Co. will post 2.85 EPS for the current fiscal year.

Insider Activity at Boston Scientific

In other news, EVP John Bradley Sorenson sold 6,528 shares of the firm’s stock in a transaction on Friday, February 7th. The stock was sold at an average price of $104.97, for a total value of $685,244.16. Following the transaction, the executive vice president now directly owns 26,449 shares in the company, valued at $2,776,351.53. This trade represents a 19.80 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, EVP Arthur C. Butcher sold 17,313 shares of the firm’s stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $101.80, for a total value of $1,762,463.40. Following the completion of the transaction, the executive vice president now owns 5,502 shares in the company, valued at approximately $560,103.60. This trade represents a 75.88 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 137,322 shares of company stock valued at $14,321,068 in the last 90 days. Corporate insiders own 0.50% of the company’s stock.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.